| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 2.7K | 2.9% |
| Total Income | 2.7K | 2.9% |
| Expenditure | 2.6K | 2.6% |
| PBT | -6.00 | 100.0% |
| Net Profit | -15.00 | 111.9% |
| OPM | 2.44% | 0.23pp |
| NPM | -0.56% | 5.35pp |
| EPS | -0.03 | 112.0% |
Baxter Reports Q1 2026 Results: Sales $2.7 Billion, Up 3%
03 May 2026 · 3 May, 6:08 pm
Summary
Baxter International Inc. reported first-quarter 2026 results, with worldwide sales from continuing operations totaling approximately $2.7 billion, a 3% increase on a reported basis. U.S. sales declined by 4% to $1.44 billion, while international sales increased by 12% to $1.27 billion. The company reported a U.S. GAAP net loss from continuing operations of ($17) million, or ($0.03) per diluted share, and an adjusted diluted EPS of $0.36. Baxter reiterated its full-year 2026 financial outlook, projecting flat to 1% reported sales growth from continuing operations.
Key Highlights
- 1
Worldwide sales from continuing operations totaled approximately $2.7 billion, increasing 3% on a reported basis.
- 2
U.S. sales from continuing operations totaled approximately $1.44 billion, declining 4% on a reported basis.
- 3
International sales from continuing operations in the first quarter totaled approximately $1.27 billion, increasing 12% on a reported basis.
- 4
On a U.S. GAAP basis, net income (loss) from continuing operations was ($17) million, or ($0.03) per diluted share.
- 5
Adjusted diluted EPS from continuing operations was $0.36, decreasing 35% due to unfavorable comparison to the prior year.
- 6
Medical Products & Therapies sales totaled approximately $1.3 billion, increasing 2% on a reported basis.
- 7
The company reiterated its full-year 2026 financial outlook, including flat to 1% reported sales growth from continuing operations.
Management Comments
Andrew Hider
Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution. Although more work remains to achieve our full potential, Baxter continues to take the decisive steps necessary to fulfill our commitment to delivering better and more consistent results for our shareholders. I want to thank our colleagues for their resilience, dedication and mission-driven focus to support the more than 350 million patients around the world who rely on us annually.
Informational and educational content only. Not investment advice.